SCHEMBL12535856

SCHEMBL12535856

COc1ccc(/C=C/c2cc(C)cc(OC)c2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.78
CYP1A1 P04798 4/20 0.78
CYP1B1 Q16678 4/20 0.78
NQO2 P16083 4/20 0.78
ESR1 P03372 3/20 0.78
ALOX5 P09917 3/20 0.78
AHR P35869 3/20 0.78
TUBB1 Q9H4B7 2/20 0.78
ABL1 P00519 2/20 0.78
TTR P02766 2/20 0.78
ABCB1 P08183 2/20 0.78
BCR P11274 2/20 0.78
CYP19A1 P11511 2/20 0.78
CYP1A2 P05177 1/20 0.78
TUBB4A P04350 1/20 0.78
TUBB P07437 1/20 0.78
TUBA3C P0DPH7 1/20 0.78
TUBA1B P68363 1/20 0.78
TUBA4A P68366 1/20 0.78
TUBB4B P68371 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312395 0.92 RELA (0.68) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL12231884 0.92 RELA (0.73) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL13409620 0.89 RELA (0.81) PTGS2CYP1A1CYP1B1NQO2ESR1
Trismethoxyresveratrol SCHEMBL918740 0.88 CYP1A1 (1.00) PTGS2CYP1A1CYP1B1NQO2ESR1
8Z-3,4',5-Trimethoxystilbene SCHEMBL1006207 0.88 CYP1A1 (1.00) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL16362233 0.88 CYP1A1 (0.77) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL13443549 0.88 CYP1A1 (0.91) PTGS2CYP1A1CYP1B1NQO2ESR1
Trismethoxyresveratrol SCHEMBL918739 0.88 CYP1A1 (1.00) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL3758141 0.88 CYP1A1 (0.91) PTGS2CYP1A1CYP1B1NQO2ESR1
SCHEMBL12535853 0.87 PTGS2 (0.80) PTGS2CYP1A1CYP1B1NQO2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20220213126-A1 SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES JOHN WAYNE CANCER INSTITUTE (US) 2022-07-07 US disclosed
US-8716355-B2 Hydroxylated tolans and related compounds in the treatment of a cancer KENT STATE UNIVERSITY (US) 2014-05-06 US disclosed
US-20110130468-A1 HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER KENT STATE UNIVERSITY (US) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234900-A1 METHODS OF ARENE ALKENYLATION CYBB, CBR3, AHR PTGS2 1773/4885CYP1A1 90/4885CYP1B1 62/4885
US-20220213126-A1 SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES TFEB, SQSTM1, BECN1 PTGS2 2350/4885CYP1A1 4569/4885CYP1B1 4335/4885
US-20110130468-A1 HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER TKT, HAAO, TTPA PTGS2 2030/4885CYP1A1 387/4885CYP1B1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.